Cellectis SA (CLLS)
3.10
0.00 (0.00%)
USD |
NASDAQ |
May 08, 16:00
3.06
-0.04
(-1.29%)
After-Hours: 06:51
Cellectis Cash from Financing (TTM): 82.86M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 82.86M |
September 30, 2023 | 36.24M |
June 30, 2023 | 30.44M |
March 31, 2023 | 13.25M |
December 31, 2022 | 1.145M |
September 30, 2022 | 4.764M |
June 30, 2022 | 5.202M |
March 31, 2022 | 45.41M |
December 31, 2021 | 47.52M |
September 30, 2021 | 61.62M |
June 30, 2021 | 81.85M |
March 31, 2021 | 39.01M |
December 31, 2020 | 27.32M |
September 30, 2020 | 13.62M |
June 30, 2020 | -3.761M |
March 31, 2020 | -4.483M |
December 31, 2019 | -3.862M |
Date | Value |
---|---|
September 30, 2019 | -2.673M |
June 30, 2019 | 0.078M |
March 31, 2019 | 231.73M |
December 31, 2018 | 236.49M |
September 30, 2018 | 237.28M |
June 30, 2018 | 274.55M |
March 31, 2018 | 44.47M |
December 31, 2017 | 41.27M |
September 30, 2017 | 40.37M |
June 30, 2017 | 1.336M |
March 31, 2017 | 0.4757M |
December 31, 2016 | 0.485M |
September 30, 2016 | 0.863M |
June 30, 2016 | 1.770M |
March 31, 2016 | 220.56M |
December 31, 2015 | 220.59M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.483M
Minimum
Mar 2020
82.86M
Maximum
Dec 2023
25.03M
Average
13.62M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
Biophytis SA | 7.617M |
DBV Technologies SA | 6.767M |
Genfit SA | -- |
Edap TMS SA | -0.9863M |
Adaptimmune Therapeutics PLC | 0.88M |